PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives

Gevaert T, Cimadamore A, Montironi R, Eckstein M (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Current Drug Targets Bentham Science Publishers

Book Volume: 22

Pages Range: 162-170

Journal Issue: 2

DOI: 10.2174/1389450121666200510015216

Abstract

Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients, immunohistochemical PD-L1 testing is now required. Several emerging issues on antibodies, test platforms and scoring algorithms have raised concerns about the comparability and interchangeability between these assays. In this review, we have focused on the interchangeability of the used algorithms and assays for PD-L1 testing in urothelial carcinoma, on the predictive reliability of PD-L1 testing in urothelial carcinoma and the potential of other new and upcoming biomarkers.

Authors with CRIS profile

Markus Eckstein Institute of Pathology

Involved external institutions

Università Politecnica delle Marche (UNIVPM) / Marche Polytechnic University IT Italy (IT) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE)

How to cite

APA:

Gevaert, T., Cimadamore, A., Montironi, R., & Eckstein, M. (2021). PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives. Current Drug Targets, 22(2), 162-170. https://doi.org/10.2174/1389450121666200510015216

MLA:

Gevaert, Thomas, et al. "PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives." Current Drug Targets 22.2 (2021): 162-170.

BibTeX: Download